Heparin versus bivalirudin for anticoagulation in adult extracorporeal membrane oxygenation: a systematic review and meta-analysis
Systematic review and meta-analysis published in ASAIO Journal (2023)
Abstract
Extracorporeal membrane oxygenation (ECMO) poses unique thrombotic and hemorrhagic risks, and the optimal anticoagulant choice is unknown. We systematically searched Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science Core Collection for randomized-, crossover-, retrospective cohort-, or parallel-designed clinical studies of adult patients receiving ECMO that compared heparin recipients with bivalirudin recipients. Meta-analysis was performed with random-effects models. The ROBINS-I tool was used to assess the risk of bias. Six retrospective observational studies met the inclusion criteria for the qualitative summary. Five studies were suitable for meta-analysis. Those who received heparin were more likely to experience circuit-related thrombosis (odds ratio [OR] 2.05, 95% confidence interval [CI] 1.25-3.37, p = 0.005, I2 = 0%) and die (OR 1.62, 95% CI 1.19-2.21, p = 0.002, I2 = 0%) compared with those who received bivalirudin. There were no differences in major bleeding events between heparin and bivalirudin recipients (OR 1.83, 95% CI 0.55-6.09, p = 0.33, I2 = 82.7%). In retrospective settings compared with heparin anticoagulation, bivalirudin was associated with less circuit-related thrombotic events and greater survival in adults supported on ECMO, without contributing to more bleeding complications. Prospective controlled studies comparing heparin and bivalirudin in adult ECMO patients are warranted to corroborate these findings.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Meta-analysis of bivalirudin vs heparin in adult ECMO. Bivalirudin associated with fewer thromboses, similar bleeding, and improved time within target aPTT range.
Por qué esto importa para la hirudoterapia
Esta revisión sistemática y metaanálisis comparó la anticoagulación con heparina frente a bivalirudina en pacientes adultos que recibieron oxigenación por membrana extracorpórea, agrupando datos de seis estudios observacionales retrospectivos (cinco aptos para el metaanálisis). Los pacientes que recibieron heparina presentaron una probabilidad significativamente mayor de experimentar trombosis relacionada con el circuito y muerte en comparación con los receptores de bivalirudina, sin diferencias significativas en los eventos de sangrado mayor entre los grupos. El resumen no aborda sanguijuelas, la obtención de hirudina ni la hirudoterapia, por lo que no puede establecerse una conexión defendible con el ámbito de la ASH a partir de este artículo por sí solo. La base de evidencia es enteramente retrospectiva y observacional, y el estudio involucra un anticoagulante farmacéutico en cuidados críticos en lugar de la terapia con sanguijuelas.
Citación
Heparin versus bivalirudin for anticoagulation in adult extracorporeal membrane oxygenation: a systematic review and meta-analysis.
Wieruszewski PM et al. · ASAIO journal, 2023
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026